Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.
Angiogenic biomarkers
placental growth factor
pre-eclampsia
soluble fms-like tyrosine kinase 1
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
09
07
2020
pubmed:
24
7
2020
medline:
15
12
2020
entrez:
24
7
2020
Statut:
ppublish
Résumé
Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing.
Identifiants
pubmed: 32701207
doi: 10.1111/1471-0528.16425
doi:
Substances chimiques
Placenta Growth Factor
144589-93-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1590-1597Subventions
Organisme : Department of Health
ID : RP-2014-05-019
Pays : United Kingdom
Informations de copyright
© 2020 Royal College of Obstetricians and Gynaecologists.
Références
Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol 2017;217:237-48.e216.
Shennan AH, Green M, Chappell LC. Maternal deaths in the UK: pre-eclampsia deaths are avoidable. Lancet 2017;389:582-4.
Steer P. The epidemiology of preterm labour. BJOG 2005;112(Suppl 1):1-3.
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. ISSHP. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24-43.
National Institute for Health and Care Excellence. Hypertension in Pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133, 2019
Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001;97:261-7.
Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, et al. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). BMJ 2009;339:b3129.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, et al. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens 2013;3:124-32.
Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3-18.
Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens 2017;31:782-6.
Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31.
National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecysys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) https://www.nice.org.uk/guidance/dg23, 2016.
Barton JR, Woelkers DA, Newman RB, Combs CA, How HY, Boggess KA, et al. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study. Am J Obstet Gynecol 2020;222:259.e1-259.e11.
Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM, et al. Placental growth factor and the risk of adverse neonatal and maternal outcomes. Obstet Gynecol 2020;135:665-73.
Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019;393:1807-18.
Duckworth S, Chappell LC, Seed PT, Mackillop L, Shennan AH, Hunter R. Placental growth factor (PlGF) in women with suspected pre-eclampsia prior to 35 weeks' gestation: a budget impact analysis. PLoS One 2016;11:e0164276.
Frampton GK, Jones J, Rose M, Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess 2016;20:1-160.
Duhig KE, Seed PT, Myers JE, Bahl R, Bambridge G, Barnfield S, et al. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. BJOG 2019;126:1390-8.
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-9.
Zeisler H, Hund M, Verlohren S. The sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:1785-6.
Cerdeira AS, O'Sullivan J, Ohuma EO, Harrington D, Szafranski P, Black R, et al. Randomized interventional study on prediction of preeclampsia/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension 2019;74:983-90.
McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study. Ultrasound Obstet Gynecol 2019;53:62-7.
Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy 2016;35:295-305.
Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205:469.e1-e8.
Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads CA, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009;88:758-65.
Black C, Al-Amin A, Rolnik DL, Kane SC, Stolarek C, White A, et al. Midpregnancy testing for soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): An inter-assay comparison of three automated immunoassay platforms. Placenta 2019;86:11-4.
Cheng YKY, Poon LCY, Shennan A, Leung TY, Sahota DS. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor. Pregnancy Hypertens 2019;17:165-71.
Duckworth S, Griffin M, Seed PT, North R, Myers J, Mackillop L, et al. Diagnostic biomarkers in women with suspected preeclampsia in a prospective multicenter study. Obstet Gynecol 2016;128:245-52.
Duhig KE, Webster LM, Sharp A, Gill C, Seed PT, Shennan AH, et al. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: a case series study. Acta Obstet Gynecol Scand 2020;99:994-1002.
Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol 2019;53:367-75.
Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012;60:451-8.
Saleh L, Tahitu SIM, Danser AHJ, van den Meiracker AH, Visser W. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies. Pregnancy Hypertens 2018;14:222-7.
Dröge L, Herraìz I, Zeisler H, Schlembach D, Stepan H, Küssel L, et al. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound Obstet Gynecol 2015;45:286-93.
Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta 2016;42:1-8.
Gaccioli F, Sovio U, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study. Lancet Child Adolesc Health 2018;2:569-81.
Griffin M, Seed PT, Duckworth S, North R, Myers J, Mackillop L, et al. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol 2018;51:387-95.
Ormesher L, Johnstone ED, Shawkat E, Dempsey A, Chmiel C, Ingram E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens 2018;14:234-9.
Griffin M, Seed PT, Webster L, Myers J, MacKillop L, Simpson N, et al. Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol 2015;46:182-90.
Ukah UV, Mbofana F, Rocha BM, Loquiha O, Mudenyanga C, Usta M, et al. Diagnostic performance of placental growth factor in women with suspected preeclampsia attending antenatal facilities in Maputo, Mozambique. Hypertension 2017;69:469-74.
Manriquez Rocha B, Mbofana F, Loquiha O, Mudenyanga C, Ukah UV, Magee LA, et al. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens 2018;11:26-31.
Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 2016;27:903-13.
Ahmed A, Williams DJ, Cheed V, Middleton LJ, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG 2020;127:478-88.